Credit Suisse Assumes Ultragenyx Pharmaceutical at Outperform, Announces Price Target of $96
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Tiago Fauth assumes Ultragenyx Pharmaceutical (NASDAQ:RARE) with an Outperform rating and announces a price target of $96.
June 14, 2023 | 9:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Credit Suisse analyst Tiago Fauth assumes Ultragenyx Pharmaceutical (NASDAQ:RARE) with an Outperform rating and a price target of $96.
The Outperform rating and price target of $96 by Credit Suisse analyst Tiago Fauth indicate a positive outlook for Ultragenyx Pharmaceutical. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100